GLP-1 Drugs Win New Uses After 20% Heart-Risk Cut, as Brain and Cancer Evidence Stays Mixed
Updated
Updated · The Conversation · Jun 2
GLP-1 Drugs Win New Uses After 20% Heart-Risk Cut, as Brain and Cancer Evidence Stays Mixed
3 articles · Updated · The Conversation · Jun 2
Summary
Semaglutide and Tirzepatide have moved beyond diabetes and obesity, with approvals tied to a 20% drop in serious heart attacks and strokes, benefits in advanced liver disease, and reduced sleep apnea severity.
Those gains stem from GLP-1 receptors being active beyond the gut—in the heart, liver, kidneys and brain—raising hopes the drugs can affect inflammation, appetite, reward pathways and other disease mechanisms.
Early signals are strongest but still unproven in cancer, addiction and endometriosis: an 86,000-person study linked GLP-1 use to 17% lower cancer risk, and a 1.3 million-person analysis found fewer opioid overdoses and alcohol intoxication.
Brain and mental-health results remain conflicted: a 204-patient Alzheimer’s study showed less brain shrinkage, but phase 3 trials in Alzheimer’s and Parkinson’s failed to slow disease, while depression findings point in opposite directions.
Safety and evidence gaps still limit wider use, with many new indications lacking randomized trials and one 200,000-plus patient study finding a 2 to 2.5 times higher pancreatitis risk alongside concerns over muscle loss and possible thyroid cancer.
As GLP-1s show promise for cancer and addiction, who will decide who gets these costly, life-altering medications?
Beyond weight loss, could GLP-1 drugs be altering our brain's reward system and our ability to feel joy?
Can a simple genetic test now predict if drugs like Ozempic will work for you, or just cause severe side effects?
GLP-1 Therapies 2025–2026: New Approvals, Cardiovascular and Cancer Benefits, and the Challenge of Access and Affordability
Overview
The report highlights how recent regulatory milestones in 2025 and 2026 have transformed GLP-1 receptor agonist drugs, expanding their use beyond traditional roles in diabetes and weight management. New oral formulations, such as Foundayo (orforglipron), are making these drugs more accessible and easier for patients to use, with fewer restrictions and improved adherence. These advances position GLP-1s as central agents in chronic disease prevention and management, reflecting a major shift in their therapeutic utility. The developments mark a new era for GLP-1 drugs, offering broader benefits and greater convenience for patients.